Warning Letter: New Sponsor, Same Violative Promotional Practices For Insomnia Drug Doral
An OPDP warning letter hits Galt Pharmaceuticals for misbranding its insomnia drug Doral with similar to concerns to those outlined in a 2014 untitled letter to the then-sponsor Sciecure.
You may also be interested in...
US FDA’s 'consistent with labeling' guidance prompts more sponsors to consider comparative promotional claims, but any minimization of product safety issues still runs the risk of enforcement, legal experts say; Office of Prescription Drug Promotion’s research agenda on consumer understanding of Rx ad claims could result in an attempt to limit comparative claims.
Promotional campaign for Stendra (avanafil) included "adult sites" as well as the American College of Cardiology's patient-focused magazine; statements that FDA found problematic in the various ads include "get hard and stay hard" and calling the product a "next generation" PDE-5 inhibitor.
The latest drug development news and highlights from our US FDA Performance Tracker.